Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 15, 2021Journal of Clinical OncologyOpen Access

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDavid A. SallmanMoffitt Cancer CenterADAmy E. DeZernSidney Kimmel Comprehensive Cancer Center
Guillermo Garcia‐Manero
Guillermo Garcia‐ManeroUniversity of Southern California

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sallman et al. (2021) studied this question.

synapsesocial.com/papers/69dffb672833447a7e255d2dhttps://doi.org/10.1200/jco.20.02341
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes2020 · 135 citations
  2. 2Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia2006 · 1,606 citations
  3. 3TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups2019 · 266 citations
  4. 4Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia2019 · 142 citations
  5. 5Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation2014 · 401 citations